BullFrog AI to Unveil New Precision AI Capability

Rhea-AI Summary

BullFrog AI (NASDAQ: BFRG) will launch a new scenario-based decision engine on March 25, 2026 to augment its bfPREP and bfLEAP platforms. The capability evaluates drug programs, trial designs, and strategic portfolio options across explicit scenarios to surface robust, risk-balanced R&D portfolios.

Key features include multi-scenario testing (e.g., capital-constrained, US-first, global), preservation of portfolio diversity, and identification of programs that succeed across multiple strategic futures.

Key Figures

Launch date: March 25 Industry R&D spend: $200 billion Clinical trial failure rate: 90%

3 metrics

Launch date March 25 Scheduled launch of new AI capability

Industry R&D spend $200 billion Annual life science and pharma R&D spending cited in release

Clinical trial failure rate 90% Estimated industry-wide clinical trial failure rate referenced

Market Reality Check

Price: $0.5549 Vol: Volume 299,335 vs 20-day ...

low vol

$0.5549 Last Close

Volume Volume 299,335 vs 20-day average 1,580,665 (0.19x normal activity). low

Technical Shares at 0.567, trading below 200-day MA of 1.33 and near 52-week low 0.5501.

Peers on Argus

Two peers in momentum scan (e.g., VSEE, ZCMD) moved down (median -26.1%), aligni...

2 Down

Two peers in momentum scan (e.g., VSEE, ZCMD) moved down (median -26.1%), aligning with weakness in BFRG and suggesting broader sector pressure.

Previous AI Reports

5 past events · Latest: Jan 27 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 27	AI data harmonization	Positive	-4.7%	bfPREP white paper outlining three-pillar framework for clinical data harmonization.
Jan 06	Oncology analytics data	Positive	-3.2%	bfLEAP analysis showing nearly threefold survival increase in pancreatic subgroups.
Dec 30	Annual shareholder letter	Positive	+2.8%	Letter detailing commercialization progress, collaborations, burn rate and 2026 catalysts.
Nov 18	Bioinformatics whitepaper	Positive	+0.9%	Whitepaper on using bfLEAP and data networks for multi-omics AI insights.
Nov 12	Conference presentation	Neutral	+0.0%	Planned bfPREP technical talk at AI Drug Discovery & Development Summit.

Pattern Detected

AI-related announcements often saw modest moves, with several positive or neutral updates met by negative price reactions.

Recent Company History

Over the last few months, BullFrog AI has repeatedly highlighted its AI platforms, including bfPREP™ data harmonization work, bfLEAP® oncology analytics, and broader bioinformatics capabilities, alongside an annual letter outlining commercialization progress and collaborations through 2028. Price reactions to prior AI-tagged news were mixed, with some positive corporate milestones coinciding with negative next-day moves. Today’s precision AI decision-engine launch continues this cadence of platform-focused updates.

Historical Comparison

AI

-0.8 %

Average Historical Move

Historical Analysis

AI-tagged updates over the last five events produced an average move of -0.84%, indicating historically muted-to-negative reactions to similar technology-focused announcements.

Typical Pattern

The AI-tagged history shows a progression from whitepapers and conference talks to clinical analytics results and commercialization updates, with the new decision engine extending the same bfPREP™/bfLEAP®-centered strategy.

Market Pulse Summary

This announcement introduces a new scenario-based AI decision engine layered over bfPREP™ and bfLEAP...

Analysis

This announcement introduces a new scenario-based AI decision engine layered over bfPREP™ and bfLEAP®, targeting portfolio strategy and clinical trial design. It continues a series of AI-tagged updates, including whitepapers, clinical analytics and commercialization plans. Investors may track the March 25 launch, adoption by pharmaceutical partners, and subsequent SEC filings or capital plans as key markers of execution and risk management.

Key Terms

clinical trial, artificial intelligence, machine learning

3 terms

clinical trial medical

"defining clinical trial strategies and building diversified, risk-balanced R&D portfolios"

A clinical trial is a carefully controlled study in which a new medicine, medical device, or treatment is tested on people to see if it is safe and effective. For investors it matters because trial results determine whether a product can win regulatory approval and reach patients, much like a road test decides if a new car can be sold; positive or negative results can sharply change a company’s prospects and stock value.

artificial intelligence technical

"a technology company using artificial intelligence (“AI”) and machine learning"

Artificial intelligence is the ability of computers and machines to perform tasks that typically require human thinking, such as understanding language, recognizing patterns, or making decisions. For investors, it matters because AI can enhance efficiency, uncover new insights, and enable smarter strategies, potentially impacting the value and performance of companies that develop or utilize this technology.

machine learning technical

"using artificial intelligence (“AI”) and machine learning to turn complex biomedical data"

Machine learning is a set of computer programs that learn patterns from large amounts of data and improve their predictions or decisions over time, like a recipe that gets better each time it’s adjusted based on taste tests. For investors it matters because these systems can speed up analysis, spot trends or risks humans might miss, automate routine work, and potentially create competitive advantages or cost savings that affect a company’s performance.

AI-generated analysis. Not financial advice.

• New capabilities to be launched on March 25
• Unique technology bolsters BullFrog AI’s end-to-end AI intelligence workflow with a scenario-based decision engine
• Advances current AI decision tools by clearly defining clinical trial strategies and building diversified, risk-balanced R&D portfolios
  
  

GAITHERSBURG, Md., Feb. 04, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence (“AI”) and machine learning to turn complex biomedical data into actionable insights, announces the coming launch of a new scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design.

The new AI capability advances the Company's end-to-end intelligence workflow by adding a strategic decision layer on top of existing platforms bfPREP™ and bfLEAP^®. Unlike traditional portfolio tools that collapse complex judgments into single scores and fixed weightings, the upcoming offering evaluates options using proprietary algorithms and methodologies revealing which programs are robust winners and which succeed only under narrow conditions.

Key capabilities include:

• Compares drug programs, indications, and trial designs without forcing arbitrary numerical scores
• Tests portfolio decisions against multiple explicit scenarios (e.g., capital-constrained, platform-building, US-first, global)
• Identifies options that perform well across strategic futures
• Preserves portfolio diversity while surfacing clear leaders to balance concentration with risk mitigation
  
  

“Each year, more than $200 billion is spent by life science and pharmaceutical companies on research and development, with very low returns given an estimated 90% clinical trial failure rate. While AI adoption in drug discovery has accelerated, strategic portfolio decisions still rely largely on manual scoring and spreadsheet-based tools that force rigid rankings on fundamentally comparative judgments,” said BullFrog AI Founder and CEO Vin Singh. “Our new capability takes a different approach by treating strategic scenarios as first-class inputs. It surfaces robust recommendations and highlights options that perform well under multiple strategic futures—enabling clear R&D strategies and the construction of diversified, risk-balanced R&D portfolios. To our knowledge, no other solution in the world can offer this capability.”

Please visit the BullFrog AI website for updates on the new product launch.

About BullFrog AI

BullFrog AI leverages artificial intelligence and machine learning to advance drug discovery and development. Through collaborations with leading research institutions, BullFrog AI uses causal AI in combination with its proprietary bfLEAP^® platform to analyze complex biological data, aiming to streamline therapeutics development and reduce failure rates in clinical trials. For more information visit BullFrog AI at: https://bullfrogai.com.

Safe Harbor Statement

This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “could,” “will,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; our and our partners’ ability to market and sell our offerings and services, including BullFrog Data Networks™; our ability to maintain compliance with Nasdaq listing rules; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

Contact:

Investors:
CORE IR
ir@bullfrogai.com

Media:
CORE PR
pr@bullfrogai.com

FAQ

What is BullFrog AI (BFRG) launching on March 25, 2026?

BullFrog AI is launching a scenario-based decision engine on March 25, 2026 to guide R&D portfolios. According to the company, the engine layers strategic scenario analysis on bfPREP and bfLEAP to evaluate programs and trial designs across multiple futures.

How does the new BFRG capability change clinical trial strategy evaluation?

The capability tests trial designs against multiple explicit scenarios rather than single scores. According to the company, this reveals which trial strategies are robust across futures and which succeed only under narrow conditions, helping prioritize trial choices.

Which BullFrog AI platforms will the new decision engine integrate with?

The decision engine integrates with bfPREP and bfLEAP to add a strategic layer to existing workflows. According to the company, the integration preserves portfolio diversity while surfacing clear leaders for risk-balanced R&D allocation.

What investor-relevant benefits does the BFRG announcement claim?

The announcement claims clearer R&D strategies and diversified, risk-balanced portfolios that highlight robust winners. According to the company, this approach aims to reduce reliance on manual scoring and mitigate concentration risk in program selection.

Does BullFrog AI (BFRG) quantify expected financial impact from the new product?

No specific revenue or financial guidance was provided with the launch announcement. According to the company, the release focuses on product capabilities and launch timing rather than quantified commercial or revenue projections.